Results 41 to 50 of about 21,053 (285)
The year in cardiology: arrhythmias and pacing. [PDF]
, 2020 During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H +4 more
core +4 more sources
Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation
Cardiology and Therapy, 2023 Introduction Treatment adherence and persistence impact the effectiveness of edoxaban for the prevention of thromboembolism in patients with atrial fibrillation (AF).
Giuseppe Patti +7 more
doaj +1 more source
Study of weight variation and dissolution of Edoxaban split tablets in pharmacy practice [PDF]
Pharmaceutical Sciences Asia, 2022 Edoxaban is available in 60 mg, 30 mg, and 15 mg unscored film-coated tablets. Tablet splitting may be an option to reduce medication costs and reduce the country’s budget.
Mantiwee Nimworapan +4 more
doaj +1 more source
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]
, 2020 OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD +12 more
core +1 more source
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source
Update on Extended Treatment for Venous Thromboembolism [PDF]
, 2018 The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge +7 more
core +2 more sources
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. [PDF]
PLoS ONE, 2014 Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with non-valvular atrial fibrillation (AF). We conducted an imputed-placebo analysis with estimates of the proportion of warfarin effect preserved by each non
Paolo Verdecchia +3 more
doaj +1 more source
Drugs in Context, 2023 Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism.
Alejandro Bimbo Diaz +8 more
doaj +1 more source
Circulation, 2022 Background: It is unknown whether the direct oral anticoagulant edoxaban can reduce leaflet thrombosis and the accompanying cerebral thromboembolic risk after transcatheter aortic valve replacement.
Duk‐Woo Park +25 more
semanticscholar +1 more source